Therapy sequencing strategies in multiple myeloma: who, what and why? - Wikidata - wikimedia - TriplyDB

Therapy sequencing strategies in multiple myeloma: who, what and why?

Therapy sequencing strategies in multiple myeloma: who, what and why?

http://www.wikidata.org/entity/Q45946305

about

BC094916 suppressed SP 2/0 xenograft tumor by down-regulating Creb1 and Bcl2 transcription

P2860

Q58741742-926C6F29-D676-4B3E-8B9C-817D6D1B577E

P2860

Therapy sequencing strategies in multiple myeloma: who, what and why?

http://www.wikidata.org/entity/Q45946305

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Therapy sequencing strategies in multiple myeloma: who, what and why?

@en

Therapy sequencing strategies in multiple myeloma: who, what and why?

@nl

type

label

Therapy sequencing strategies in multiple myeloma: who, what and why?

@en

Therapy sequencing strategies in multiple myeloma: who, what and why?

@nl

prefLabel

Therapy sequencing strategies in multiple myeloma: who, what and why?

@en

Therapy sequencing strategies in multiple myeloma: who, what and why?

@nl

P1433

Q45946305-203E6276-A524-46EE-BBC1-58BE535D3ABE

P1476

Q45946305-40E46A7F-D91D-4BA5-B459-B563B5EC6652

P2093

Q45946305-4826BC7E-2FA5-4ECC-9624-0856890B4931

Q45946305-CA1560CC-3A66-4D50-97C2-82A8864A3AE7

P2860

Q45946305-072FC10A-4577-4267-AE65-6AE013959CE8

Q45946305-0954F926-8789-4940-BE2C-CCE17FEF52CC

Q45946305-0E40540E-D07A-4028-BC59-832EE43F043E

Q45946305-10C23474-A3F1-4716-8AD6-6304C1F72C46

Q45946305-188D1123-21DA-4DB6-810B-E0E72E6A0CAA

Q45946305-42BD2FC6-1C48-4BBA-9A53-37774BA316C9

Q45946305-42D44166-829B-4647-B23A-8F912736C404

Q45946305-45AD0BF7-EB44-40C2-8407-643D19D838C3

Q45946305-472D9F93-6F29-4FDE-8882-02E0462C79D0

Q45946305-57E63ADF-2F72-4C46-BCF9-2A412A8E567A

P31

Q45946305-280213c4-2c05-4da8-85a2-ec77281d2fd1

Q45946305-30D0250E-5064-448F-8760-F2CE83D4D1A3

P356

Q45946305-19FDCDA7-3F0F-44DD-93E9-984BD00CBEFB

P407

Q45946305-656158E4-F1BE-4EC6-8A24-4235BC4B3386

P577

Q45946305-D151316B-912C-475A-8332-B3134C2B7E80

P698

Q45946305-440EE79A-B1FB-4281-8094-BD28FE2286F3

P356

P1433

Future Oncology

P1476

Therapy sequencing strategies in multiple myeloma: who, what and why?

@en

P2093

Caitlin Costello

http://www.w3.org/2001/XMLSchema#string

Joseph R Mikhael

http://www.w3.org/2001/XMLSchema#string

P2860

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.

Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides

P31

scholarly article

P356

10.2217/FON-2017-0493

http://www.w3.org/2001/XMLSchema#string

P407

P577

2017-12-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29219615

http://www.w3.org/2001/XMLSchema#string